ciglitazone has been researched along with Insulin Resistance in 18 studies
ciglitazone: structure given in second source; PPAR agonist used for type II diabetes
ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.
Insulin Resistance: Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ciglitazone (5-4-(1-methylcyclohexyfmethoxy)benzyl-thiazolidine-2,4-dione) is a hypoglycemic agent, which has been shown to improve blood glucose levels and in vitro insulin sensitivity in some genetically hyperglycemic rodents." | 7.67 | A potent in vivo effect of ciglitazone on muscle insulin resistance induced by high fat feeding of rats. ( Chisholm, DJ; James, DE; Jenkins, AB; Kraegen, EW; Storlien, LH, 1989) |
| " Treatment of ob/ob mice with ciglitazone, a new oral hypoglycaemic, led to a restoration of insulin sensitivity in brown adipose tissue." | 7.67 | Effects of ciglitazone on insulin resistance and thermogenic responsiveness to acute cold in brown adipose tissue of genetically obese (ob/ob) mice. ( Mercer, SW; Trayhurn, P, 1986) |
| " Chronic administration of ADD-3878 for as long as 12 wk to young yellow KK mice, which were in the early stage of diabetes and obesity, depressed age-dependent rises in blood glucose, plasma triglyceride, and insulin without exerting any effect on obesity." | 5.27 | Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, ciglitazone), a new antidiabetic agent. ( Fujita, T; Iwatsuka, H; Kawamatsu, Y; Sohda, T; Sugiyama, Y; Suzuoki, Z; Taketomi, S, 1983) |
| "Ciglitazone was the first insulin sensitizer with a thiazolidinedione structure to reduce insulin resistance and hyperglycemia and many thiazolidinedione derivatives (TZDs) have since been reported as insulin sensitizers." | 4.80 | [Mechanisms of thiazolidinedione derivatives for hypoglycemic and insulin sensitizing effects]. ( Ikeda, H; Murase, K; Sugiyama, Y, 2000) |
| "Ciglitazone (5-4-(1-methylcyclohexyfmethoxy)benzyl-thiazolidine-2,4-dione) is a hypoglycemic agent, which has been shown to improve blood glucose levels and in vitro insulin sensitivity in some genetically hyperglycemic rodents." | 3.67 | A potent in vivo effect of ciglitazone on muscle insulin resistance induced by high fat feeding of rats. ( Chisholm, DJ; James, DE; Jenkins, AB; Kraegen, EW; Storlien, LH, 1989) |
| " Treatment of ob/ob mice with ciglitazone, a new oral hypoglycaemic, led to a restoration of insulin sensitivity in brown adipose tissue." | 3.67 | Effects of ciglitazone on insulin resistance and thermogenic responsiveness to acute cold in brown adipose tissue of genetically obese (ob/ob) mice. ( Mercer, SW; Trayhurn, P, 1986) |
| "Insulin resistance is a characteristic feature of type II diabetes as well as obesity." | 2.41 | [Discovery and development of a new insulin sensitizing agent, pioglitazone]. ( Fujita, T; Ikeda, H; Kawamatsu, Y; Meguro, K; Sohda, T, 2002) |
| "Troglitazone was designed to combine tocopherol, anti-peroxidant, and thiazolidinedione." | 2.41 | [The development of thiazolidinedione drugs as anti-diabetic agents]. ( Kuzuya, T, 2000) |
| "Insulin resistance is the failure of insulin to stimulate the transport of glucose into its target cells." | 1.35 | Nuclear receptor agonists improve insulin responsiveness in cultured cardiomyocytes through enhanced signaling and preserved cytoskeletal architecture. ( Lerch, R; Montessuit, C; Papageorgiou, I, 2008) |
| " Chronic administration of ADD-3878 for as long as 12 wk to young yellow KK mice, which were in the early stage of diabetes and obesity, depressed age-dependent rises in blood glucose, plasma triglyceride, and insulin without exerting any effect on obesity." | 1.27 | Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, ciglitazone), a new antidiabetic agent. ( Fujita, T; Iwatsuka, H; Kawamatsu, Y; Sohda, T; Sugiyama, Y; Suzuoki, Z; Taketomi, S, 1983) |
| " To see the dose-response of insulin, a second experiment was carried out in which portions of the fat pads were incubated in vitro with glucose-1-14C in the presence of 0-40 ng/ml insulin and isolated adipocytes were used to estimate for 125I-insulin binding." | 1.27 | Ciglitazone, a new hypoglycemic agent. II. Effect on glucose and lipid metabolisms and insulin binding in the adipose tissue of C57BL/6J-ob/ob and -+/? mice. ( Chang, AY; Gilchrist, BJ; Wyse, BM, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (38.89) | 18.7374 |
| 1990's | 3 (16.67) | 18.2507 |
| 2000's | 7 (38.89) | 29.6817 |
| 2010's | 1 (5.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sohda, T | 3 |
| Mizuno, K | 1 |
| Momose, Y | 1 |
| Ikeda, H | 3 |
| Fujita, T | 4 |
| Meguro, K | 2 |
| Tanis, SP | 1 |
| Colca, JR | 1 |
| Parker, TT | 1 |
| Artman, GD | 1 |
| Larsen, SD | 1 |
| McDonald, WG | 1 |
| Gadwood, RC | 1 |
| Kletzien, RF | 1 |
| Zeller, JB | 1 |
| Lee, PH | 1 |
| Adams, WJ | 1 |
| Lopez, V | 1 |
| Saraff, K | 1 |
| Medh, JD | 1 |
| Kawamatsu, Y | 2 |
| Zirlik, A | 1 |
| Leugers, A | 1 |
| Lohrmann, J | 1 |
| Ernst, S | 1 |
| Sobel, BE | 1 |
| Bode, C | 1 |
| Nordt, TK | 1 |
| Montessuit, C | 1 |
| Papageorgiou, I | 1 |
| Lerch, R | 1 |
| Ozel Demiralp, D | 1 |
| Aktas, H | 1 |
| Akar, N | 1 |
| Kirsch, DM | 1 |
| Bachmann, W | 1 |
| Häring, HU | 1 |
| Sugiyama, Y | 2 |
| Taketomi, S | 2 |
| Iwatsuka, H | 1 |
| Suzuoki, Z | 1 |
| Chang, AY | 1 |
| Wyse, BM | 1 |
| Gilchrist, BJ | 1 |
| Umeda, F | 1 |
| Petrie, J | 1 |
| Small, M | 1 |
| Connell, J | 1 |
| Kuzuya, T | 1 |
| Murase, K | 1 |
| Trimble, ER | 1 |
| Bruzzone, R | 1 |
| Belin, D | 1 |
| Kraegen, EW | 1 |
| James, DE | 1 |
| Jenkins, AB | 1 |
| Chisholm, DJ | 1 |
| Storlien, LH | 1 |
| Yokono, K | 1 |
| Mercer, SW | 1 |
| Trayhurn, P | 1 |
4 reviews available for ciglitazone and Insulin Resistance
| Article | Year |
|---|---|
[Discovery and development of a new insulin sensitizing agent, pioglitazone].
Topics: Animals; Clinical Trials as Topic; Clofibrate; Diabetes Mellitus; Diabetes Mellitus, Experimental; D | 2002 |
Potential role of thiazolidinediones in older diabetic patients.
Topics: Aged; Aging; Animals; Benzopyrans; Chromans; Diabetes Mellitus, Type 2; Double-Blind Method; Glucose | 1995 |
[The development of thiazolidinedione drugs as anti-diabetic agents].
Topics: Animals; Chemical and Drug Induced Liver Injury; Chromans; Clinical Trials as Topic; Diabetes Mellit | 2000 |
[Mechanisms of thiazolidinedione derivatives for hypoglycemic and insulin sensitizing effects].
Topics: Animals; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipid Metaboli | 2000 |
14 other studies available for ciglitazone and Insulin Resistance
| Article | Year |
|---|---|
Studies on antidiabetic agents. 11. Novel thiazolidinedione derivatives as potent hypoglycemic and hypolipidemic agents.
Topics: Animals; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resista | 1992 |
PPARγ-sparing thiazolidinediones as insulin sensitizers. Design, synthesis and selection of compounds for clinical development.
Topics: Dose-Response Relationship, Drug; Drug Design; Humans; Insulin Resistance; Molecular Structure; PPAR | 2018 |
Down-regulation of lipoprotein lipase increases glucose uptake in L6 muscle cells.
Topics: Animals; Cell Line; Down-Regulation; Glucose; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipo | 2009 |
Direct attenuation of plasminogen activator inhibitor type-1 expression in human adipose tissue by thiazolidinediones.
Topics: Adipocytes; Adipose Tissue; Cells, Cultured; Chromans; Humans; Hypoglycemic Agents; Insulin Resistan | 2004 |
Nuclear receptor agonists improve insulin responsiveness in cultured cardiomyocytes through enhanced signaling and preserved cytoskeletal architecture.
Topics: Alitretinoin; AMP-Activated Protein Kinase Kinases; Animals; Cells, Cultured; Cytoskeleton; Glucose; | 2008 |
The effect of plasminogen activator inhibitor-1 -675 4G/5G polymorphism on PAI-1 gene expression and adipocyte differentiation.
Topics: 3T3-L1 Cells; Adipocytes; Animals; Cell Differentiation; Cells, Cultured; Chromans; Humans; Insulin | 2008 |
Ciglitazone reverses cAMP-induced post-insulin receptor resistance in rat adipocytes in vitro.
Topics: 3-O-Methylglucose; Adipose Tissue; Animals; Biological Transport; Cyclic AMP; Insulin; Insulin Resis | 1984 |
Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, ciglitazone), a new antidiabetic agent.
Topics: Animals; Blood Glucose; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Experimental; Dogs; Fatty | 1983 |
Ciglitazone, a new hypoglycemic agent. II. Effect on glucose and lipid metabolisms and insulin binding in the adipose tissue of C57BL/6J-ob/ob and -+/? mice.
Topics: Adipose Tissue; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Fatty Acids, Nonesterified; | 1983 |
"Glitazones", a prospect for non-insulin-dependent diabetes.
Topics: Chromans; Diabetes Mellitus, Type 2; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistanc | 1997 |
Insulin resistance is accompanied by impairment of amylase-gene expression in the exocrine pancreas of the obese Zucker rat.
Topics: Amylases; Animals; Female; Gene Expression Regulation; Glucose; Insulin Resistance; Obesity; Pancrea | 1986 |
A potent in vivo effect of ciglitazone on muscle insulin resistance induced by high fat feeding of rats.
Topics: Animals; Blood Glucose; Deoxyglucose; Dietary Fats; Hypoglycemic Agents; Insulin; Insulin Resistance | 1989 |
Insulin receptor and postbinding defects in KK mouse adipocytes and improvement by ciglitazone.
Topics: 3-O-Methylglucose; Adipose Tissue; Animals; Carbon Radioisotopes; Cells, Cultured; Diabetes Mellitus | 1988 |
Effects of ciglitazone on insulin resistance and thermogenic responsiveness to acute cold in brown adipose tissue of genetically obese (ob/ob) mice.
Topics: Adipose Tissue, Brown; Animals; Cold Temperature; Guanosine Diphosphate; Insulin; Insulin Resistance | 1986 |